NR3C1 and Cushing syndrome: Preclinical research suggests that recently developed non-steroidal GR antagonists, such as CORT125134, which accomplished phase III clinical trial for Cushing’s syndrome, hold therapeutic potential for the treatment of diseases associated with GR overactivation [77].